share_log

10-Q: Q3 2024 Earnings Report

10-Q: Q3 2024 Earnings Report

10-Q:2024財年三季報
美股SEC公告 ·  2024/11/20 06:17

Moomoo AI 已提取核心訊息

ENDRA Life Sciences reported financial results for Q3 2024, with net loss decreasing to $2.35 million compared to $3.10 million in Q3 2023. Research and development expenses declined 51% to $794,444, while sales and marketing expenses decreased 66% to $83,157, reflecting the company's transition from product development to commercialization focus.The company ended the quarter with $4.75 million in cash and working capital of $4.15 million. Management is pursuing additional financing options to support ongoing operations and commercialization plans, including potential sales of common stock through their at-the-market program. However, the company noted material concerns about its ability to continue as a going concern without securing adequate additional funding.ENDRA continues to advance its TAEUS technology platform, with plans to complete necessary clinical studies by Q4 2024 or Q1 2025 and submit a new de novo FDA request in H1 2025. The company has restructured its European sales operations and appointed Alexander Tokman as CEO and Chairman in August 2024 to lead its commercialization strategy.
ENDRA Life Sciences reported financial results for Q3 2024, with net loss decreasing to $2.35 million compared to $3.10 million in Q3 2023. Research and development expenses declined 51% to $794,444, while sales and marketing expenses decreased 66% to $83,157, reflecting the company's transition from product development to commercialization focus.The company ended the quarter with $4.75 million in cash and working capital of $4.15 million. Management is pursuing additional financing options to support ongoing operations and commercialization plans, including potential sales of common stock through their at-the-market program. However, the company noted material concerns about its ability to continue as a going concern without securing adequate additional funding.ENDRA continues to advance its TAEUS technology platform, with plans to complete necessary clinical studies by Q4 2024 or Q1 2025 and submit a new de novo FDA request in H1 2025. The company has restructured its European sales operations and appointed Alexander Tokman as CEO and Chairman in August 2024 to lead its commercialization strategy.
ENDRA Life Sciences公佈了2024年第三季度的財務結果,淨虧損減少至235萬美元,相較於2023年第三季度的310萬美元。研發支出下降51%,至794,444美元,而銷售和市場費用下降66%,至83,157美元,這反映了公司從產品開發轉向商業化的重點。公司在本季度末擁有475萬美元的現金和415萬美元的營運資金。管理層正在尋求額外的融資方案,以支持持續的運營和商業化計劃,包括通過市場計劃可能銷售普通股。然而,公司指出,若未能獲得足夠的額外資金,將面臨持續經營能力方面的重大擔憂。ENDRA繼續推進其TAEUS科技平台,計劃在2024年第四季度或2025年第一季度完成必要的臨牀研究,並在2025年上半年提交新的de novo FDA申請。公司已重組其歐洲銷售業務,並於2024年8月任命亞歷山大·托克曼爲首席執行官和董事長,以領導其商業化策略。
ENDRA Life Sciences公佈了2024年第三季度的財務結果,淨虧損減少至235萬美元,相較於2023年第三季度的310萬美元。研發支出下降51%,至794,444美元,而銷售和市場費用下降66%,至83,157美元,這反映了公司從產品開發轉向商業化的重點。公司在本季度末擁有475萬美元的現金和415萬美元的營運資金。管理層正在尋求額外的融資方案,以支持持續的運營和商業化計劃,包括通過市場計劃可能銷售普通股。然而,公司指出,若未能獲得足夠的額外資金,將面臨持續經營能力方面的重大擔憂。ENDRA繼續推進其TAEUS科技平台,計劃在2024年第四季度或2025年第一季度完成必要的臨牀研究,並在2025年上半年提交新的de novo FDA申請。公司已重組其歐洲銷售業務,並於2024年8月任命亞歷山大·托克曼爲首席執行官和董事長,以領導其商業化策略。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息